Editor: Qun Zhou

Series Title: Recent Advances in Biotechnology

Recent Progress in Glycotherapy

Volume 3

eBook: US $89 Special Offer (PDF + Printed Copy): US $163
Printed Copy: US $119
Library License: US $356
ISSN: 2468-5364 (Print)
ISSN: 2468-5372 (Online)
ISBN: 978-1-68108-392-6 (Print)
ISBN: 978-1-68108-391-9 (Online)
Year of Publication: 2016
DOI: 10.2174/97816810839261160301


Carbohydrates (monosaccharides, oligosaccharides and polysaccharides) exist naturally in free from and as components of other macromolecules (nucleic acids, proteins and lipids). Glycotherapy refers to this use of carbohydrates or glycoengineered macromolecules in fighting life-threatening diseases. Although glycotherapy is a relatively new and limited field of pharmacology, significant progress has been made in recent years in academia and the pharmaceutical industry facilitated by advances in enzymology and recombinant DNA technologies. Consequently, carbohydrate containing biologics are now used in therapeutic regimens.

This volume provides a summary of the progress made in developing therapeutic solutions using glycoengineering techniques. Topics covered in this volume include the development of vaccines and antibodies against tumor-associated carbohydrate antigens for cancer treatment, the use of glycan for viral inhibition, glycoPEGylation, hyaluronic acid conjugation, and protein modification and conjugation for increasing therapeutic index using recombinant and chemoenzymatic approaches. The volume is essential reading for biochemists, pharmacologists and R&D professionals interested in glycotherapy.


This book includes a timely collection of topics addressing important advances in glycotechnology that are being exploited in the development of glycotherapeutics.

This area is rooted in the rich history of the chemistry of carbohydrates that contributed to defining the structures of oligosaccharides and developed the complex synthesis of these exquisite molecules. In addressing the functions of these structures in animal cells glycobiologists, using the major advances in biochemistry and molecular biology developed in the last decades of the 20th century, unraveled the complex process involved in the biosynthesis, assembly, and processing of glycoproteins, glycolipids and proteoglycans. One of the seminal observations that initiated the general area of glycobiology was Victor Ginsburg’s discovery in the early 1960’s that neuraminidase digestion of lymphocytes altered their normal trafficking pattern, which ultimately led to the discovery of the animal cell lectins, and we now know that the functions of mammalian cell glycans are somehow associated with either direct or indirect protein-glycan interactions making them ideal candidates for glycotherapeutic studies with many examples already available.

The obvious challenge now resides in the continued search for the roles of glycans in normal physiology and disease; and these advances a coming rapidly in the field we now refer to as Glycomics, which has recently been recognized as a strategic area for NIH Common Fund support. The future is indeed bright, and the opportunities are ripe for the investigators to exploit this rapidly expanding area for glycotherapy.

David F. Smith
Emory Comprehensive Glycomics Core
Emory University School of Medicine
Atlanta, GA 30322
E-mail: dfsmith@emory.edu


.Textbook of Advanced Dermatology: Pearls for Academia and Skin Clinics (Part 1).
.Heterocyclic Anti-Inflammatory Agents: A Guide for Medicinal Chemists.
.Precision Medicine and Human Health.
.Quick Guide in History Taking and Physical Examination.